NCT06216496

Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer

Name: Clinical Trial NCT06216496
Creator: University Hospital, Grenoble
Keywords: Ovarian Cancer, dynamic test for amino acid metabolism, other, clinical trial

Evaluation of Amino Acid Metabolism Changes in Participants With Ovarian Cancer by Dynamic Test

University Hospital, Grenoble·ClinicalTrials.gov·otherNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Ovarian Cancer
Drug/Device/Intervention: dynamic test for amino acid metabolism
Study type: Interventional
Intervention type: other

Sponsor & location

Primary sponsor: University Hospital, Grenoble

Timeline & enrollment

Phase: N/A
Start date: Jan 01, 2024
End date: Dec 01, 2026
Enrollment: 23 participants

Primary outcome

metabolism of each amino acid, in women with non-immediately resectable ovarian cancer (with or without peritoneal metastases) of high-grade serous type.

Summary

Ovarian cancer is associated with undernutrition in more than half of all cases. The current management of undernutrition-cachexia in cancer is not specific. It is well recognized that the nutritional support currently offered to cancer patients is not effective in combating cachexia, which progresses inexorably, leading to the patient's death. It is therefore necessary to offer specific and adapted care, in particular by optimizing the quality of nitrogen intake. To achieve this, the investigators first need to define the specific amino acid requirements of cancer patients.

ICD-10 classifications

Malignant neoplasm of ovarySecondary malignant neoplasm of ovaryBenign neoplasm of ovaryOvarian pregnancyOvarian dysfunction

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06216496
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06216496 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Grenoble and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 23 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.